Published in Oncology (Williston Park) on November 30, 2010
Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. Cancer Biol Ther (2013) 1.26
Future directions of monoclonal antibody use in personalized lung cancer therapy. Oncology (Williston Park) (2010) 0.75
Bevacizumab in advanced lung cancer: in search of the right drug for the right patient. Oncology (Williston Park) (2010) 0.75
Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst (2003) 3.41
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol (2012) 3.04
NF-kappaB and virus infection: who controls whom. EMBO J (2003) 2.08
Compliance with therapy in hypertensive patients. Intern Emerg Med (2006) 1.66
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol (2007) 1.60
Transcription of Satellite III non-coding RNAs is a general stress response in human cells. Nucleic Acids Res (2007) 1.58
Comparative genome analysis of Trichophyton rubrum and related dermatophytes reveals candidate genes involved in infection. MBio (2012) 1.55
Treating advanced non-small cell lung cancer in the elderly. Ther Adv Med Oncol (2010) 1.53
A diastrophic dysplasia sulfate transporter (SLC26A2) mutant mouse: morphological and biochemical characterization of the resulting chondrodysplasia phenotype. Hum Mol Genet (2005) 1.43
The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist (2008) 1.39
Treatment of pulmonary neuroendocrine tumours: state of the art and future developments. Cancer Treat Rev (2012) 1.37
Collagen plays an active role in the aggregation of beta2-microglobulin under physiopathological conditions of dialysis-related amyloidosis. J Biol Chem (2006) 1.33
Treatment of advanced non small cell lung cancer. J Thorac Dis (2011) 1.32
Proinflammatory cytokines and cardiac abnormalities in uncomplicated obesity: relationship with abdominal fat deposition. Nutr Metab Cardiovasc Dis (2006) 1.27
Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. Cancer Biol Ther (2013) 1.26
Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist (2007) 1.26
Dermatophytes: host-pathogen interaction and antifungal resistance. An Bras Dermatol (2010) 1.23
Herpes simplex virus disrupts NF-kappaB regulation by blocking its recruitment on the IkappaBalpha promoter and directing the factor on viral genes. J Biol Chem (2006) 1.22
The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments. Oncologist (2007) 1.20
Heparin strongly enhances the formation of beta2-microglobulin amyloid fibrils in the presence of type I collagen. J Biol Chem (2007) 1.18
Phenotypic features of carbohydrate sulfotransferase 3 (CHST3) deficiency in 24 patients: congenital dislocations and vertebral changes as principal diagnostic features. Am J Med Genet A (2010) 1.17
Congenital joint dislocations caused by carbohydrate sulfotransferase 3 deficiency in recessive Larsen syndrome and humero-spinal dysostosis. Am J Hum Genet (2008) 1.15
Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist (2007) 1.14
Chondrodysplasia and abnormal joint development associated with mutations in IMPAD1, encoding the Golgi-resident nucleotide phosphatase, gPAPP. Am J Hum Genet (2011) 1.12
Antifungal resistance mechanisms in dermatophytes. Mycopathologia (2008) 1.10
Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis. Dig Liver Dis (2010) 1.09
Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer. J Thorac Oncol (2007) 1.07
Treatment of advanced non-small-cell lung cancer in the elderly. Lung Cancer (2009) 1.07
Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. Oncogene (2003) 1.06
Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer. Oncologist (2009) 1.05
Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer (2003) 1.04
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. Lung Cancer (2010) 1.03
ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. Target Oncol (2013) 1.02
Differential expression of both extracellular and intracellular proteins is involved in the lethal or nonlethal phenotypic variation of BrtlIV, a murine model for osteogenesis imperfecta. Proteomics (2007) 1.01
Interaction of decorin with CNBr peptides from collagens I and II. Evidence for multiple binding sites and essential lysyl residues in collagen. Eur J Biochem (2002) 1.01
Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy. Stem Cells (2012) 1.00
Lung cancer in the elderly. J Clin Oncol (2007) 1.00
Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies. J Clin Oncol (2007) 0.99
Molecular diagnosis of analbuminemia: a novel mutation identified in two Amerindian and two Turkish families. Clin Chem (2002) 0.99
Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line? Oncologist (2009) 0.99
Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy. Oncologist (2009) 0.97
The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. Crit Rev Oncol Hematol (2008) 0.96
The pH signaling transcription factor PacC mediates the growth of Trichophyton rubrum on human nail in vitro. Med Mycol (2006) 0.94
Medical treatment of small cell lung cancer: state of the art and new development. Expert Opin Pharmacother (2013) 0.94
Beta2-microglobulin isoforms display an heterogeneous affinity for type I collagen. Protein Sci (2005) 0.94
Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial. J Thorac Oncol (2007) 0.93
Defective proteoglycan sulfation of the growth plate zones causes reduced chondrocyte proliferation via an altered Indian hedgehog signalling. Matrix Biol (2010) 0.92
A novel splicing mutation causes an undescribed type of analbuminemia. Biochim Biophys Acta (2002) 0.90
Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Anticancer Res (2009) 0.90
Tumor-related leucocytosis and chemotherapy-induced neutropenia: linked or independent prognostic factors for advanced non-small cell lung cancer? Lung Cancer (2009) 0.90
Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study. J Thorac Oncol (2007) 0.89
Further delineation of CANT1 phenotypic spectrum and demonstration of its role in proteoglycan synthesis. Hum Mutat (2012) 0.89
A transcript finishing initiative for closing gaps in the human transcriptome. Genome Res (2004) 0.89
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. Lung Cancer (2010) 0.88
EURTAC first-line phase III randomized study in advanced non-small cell lung cancer: Erlotinib works also in European population. J Thorac Dis (2012) 0.88
Self-aggregation of fibrillar collagens I and II involves lysine side chains. Micron (2006) 0.88
The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer. Expert Opin Investig Drugs (2010) 0.88
Erlotinib in the treatment of non-small cell lung cancer: current status and future developments. Anticancer Res (2010) 0.88
Characterization of a new PEPD allele causing prolidase deficiency in two unrelated patients: natural-occurrent mutations as a tool to investigate structure-function relationship. J Hum Genet (2004) 0.88
Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues. Expert Opin Biol Ther (2008) 0.88
Management of unfit older patients with advanced NSCLC. Cancer Treat Rev (2009) 0.87
Transcriptional profiling reveals the expression of novel genes in response to various stimuli in the human dermatophyte Trichophyton rubrum. BMC Microbiol (2010) 0.87
A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics. Clin Lung Cancer (2007) 0.87
Advances in chemotherapy in advanced non-small-cell lung cancer. Expert Opin Pharmacother (2010) 0.87
A "live" biopsy in a small-cell lung cancer patient by detection of circulating tumor cells. Lung Cancer (2009) 0.87
Role of pH in the pathogenesis of dermatophytoses. Mycoses (2011) 0.86
Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer. Oncologist (2009) 0.86
New molecular targets in the treatment of NSCLC. Curr Pharm Des (2013) 0.86
Pemetrexed in advanced non-small cell lung cancer. Expert Opin Drug Saf (2011) 0.85
N-benzyloxycarbonyl-L-proline: an in vitro and in vivo inhibitor of prolidase. Biochim Biophys Acta (2005) 0.85
A splice variant of the Neurospora crassa hex-1 transcript, which encodes the major protein of the Woronin body, is modulated by extracellular phosphate and pH changes. FEBS Lett (2008) 0.85
Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous non-small-cell lung cancer. Clin Lung Cancer (2012) 0.85
Transcriptional profiling reveals genes in the human pathogen Trichophyton rubrum that are expressed in response to pH signaling. Microb Pathog (2009) 0.84
A quantitative and qualitative method for direct 2-DE analysis of murine cartilage. Proteomics (2007) 0.84
Physiological performance of a detergent decellularized heart valve implanted for 15 months in Vietnamese pigs: surgical procedure, follow-up, and explant inspection. Artif Organs (2012) 0.84
Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management. Curr Drug Saf (2016) 0.83
New avenues for second-line treatment of metastatic non-small-cell lung cancer. Expert Rev Anticancer Ther (2009) 0.83
First-line chemotherapy with fluorouracil and folinic acid for advanced colorectal cancer in elderly patients: a phase II study. J Clin Gastroenterol (2003) 0.83
Alteration of proteoglycan sulfation affects bone growth and remodeling. Bone (2013) 0.83
A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics. Clin Lung Cancer (2013) 0.83
A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics. Clin Lung Cancer (2007) 0.83
Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials. Lung Cancer (2012) 0.83
Matrix disruptions, growth, and degradation of cartilage with impaired sulfation. J Biol Chem (2012) 0.82
Human recombinant prolidase from eukaryotic and prokaryotic sources. Expression, purification, characterization and long-term stability studies. FEBS J (2006) 0.82
Subcutaneous angioleiomyoma of the nasal tip. Report of a rare case. In Vivo (2012) 0.82
Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines. Lung Cancer (2011) 0.82
Targeted therapies and non-small-cell lung cancer: new developments. Curr Opin Oncol (2007) 0.82
Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study. Anticancer Res (2003) 0.82
The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer. Expert Opin Ther Targets (2012) 0.82
The potential role of bevacizumab in early stages and locally advanced non-small cell lung cancer. Ther Adv Med Oncol (2009) 0.81
Differential response to intracellular stress in the skin from osteogenesis imperfecta Brtl mice with lethal and non lethal phenotype: a proteomic approach. J Proteomics (2012) 0.81